Alzheimer's Drug Discovery Foundation (ADDF)
The Alzheimer's Drug Discovery Foundation (ADDF) is a biomedical venture philanthropy and 501(c)(3) public charity that funds breakthrough research in academia and biotech to accelerate the development of drugs to prevent, treat, and cure Alzheimer's disease and related dementias. Since 1998, it has awarded over $300 million in research grants worldwide.
80% of their portfolio is in Healthcare. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-a (40% of deals). Average disclosed round size is $11.4M (across 3 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Philip Lovett
Founding Partner, Millennium Partners
Gary M. Lauder
Managing Director, Lauder Partners LLC
Niranjan Bose, PhD
Managing Director, Health and Life Sciences, Gates Ventures, LLC
Carol Seabrook Boulanger
Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP
Philip Scheltens, MD, PhD
Partner & Head of the Dementia Fund, EQT Group, Amsterdam
Tom Scanlan
Partner, Spencer Stuart
Betsy Mills, PhD
Associate Director, Aging and Alzheimer’s Prevention
Chandra Gruber
Director, Grants Management
Christine Scerra
Senior Director, Special Events and Development Operations
David Dolby
Chief Executive Officer, Dolby Family Ventures; Director, Dolby Laboratories; Director, Cogstate Limited; Chief Financial Officer, Ray and Dagmar Dolby Family Fund
David Silver
Senior Director Philanthropy and Partnerships
Emily Berkowitz
Senior Director, Communications
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Circular Genomics | Series A | $15M | Dec 2025 |
 C2N Diagnostics | Unknown | $7.0M | Sep 2024 |
 NeuroTherapia | Series B | $12.3M | Aug 2024 |
 Superfluid DX | Series A | — | Dec 2023 |
 Imeka Solutions inc. | Unknown | — | Oct 2023 |
Top Co-Investors
Last updated: 8 September 2026